Across the CML cell line panel, K562 had comparatively high SRPK1 and SRPK2 levels (Supplementary Figure S1D), suggesting that Kasumi-1 and K562 might exhibit differential responses to SRPK1 inhibition by SPHINX. The gene discussed is SRPK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.